tolcapone
- Oceanside PharmaceuticalsPart of Bausch Health, the company behind Tasmar
-
100 mgtablet
-
68682-938-9011-digit: 68682-0938-9090 tablets per bottle
-
Source: FDA, updated October 30, 2026
Generic name: tolcapone
Used for: Parkinson’s disease
Ask for the cash price
Authorized generic
Tasmar itself, without the brand name. It usually costs less than Tasmar.
The FDA has approved a generic, but it isn’t in pharmacies yet.
Details for each option
We didn’t find a savings card or cash price from Tasmar’s maker. Ask the pharmacy for Tasmar’s cash price. With insurance, ask what your plan charges.
The same medicine as Tasmar, without the brand name. Give the pharmacy its NDC to get it.
tolcapone
Source: FDA, updated October 30, 2026
“Before you fill my Tasmar, can you tell me what I’d pay for the brand, for the authorized generic from Oceanside Pharmaceuticals (NDC 68682-938-90)?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
Same active and inactive ingredients as Tasmar.
Active: tolcapone 100 mg
Inactive, on both labels:
The FDA has approved a generic, but it isn’t in pharmacies yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the authorized generic is the lower-cost way to get Tasmar.
INDICATIONS:
TASMAR is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because TASMAR, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from TASMAR.
The effectiveness of TASMAR was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see CLINICAL PHARMACOLOGY: Clinical Studies).
Source: the FDA label for Tasmar (Bausch Health US LLC), October 2, 2020. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tasmar/